You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

Xpert Xpress SARS-CoV-2 Test
Home / Tests / Oncology/Genetics / Xpert Breast Cancer STRAT4

Xpert® Breast Cancer STRAT4

Semi-quantitative measurement of ESR1, PGR, ERBB2, and MKi67 from FFPE invasive breast cancer tissue in 2 hours

Ordering Info

Used in conjunction with GeneXpert® technology, Xpert Breast Cancer STRAT4 simplifies breast cancer biomarker assessment through semi-automated sample preparation, automated RNA isolation, reverse transcription, amplification by real-time PCR and detection. The entire process happens within a patented cartridge-based system.

The Need


Breast cancer biomarker ER/PGR/HER2/Ki-67 results need to be dependable and objective

  • Clinicians need more reliable ER/PGR/HER2/Ki-67 assessment in FFPE tumor tissues.
  • 5% of HER2 IHC results are equivocal based upon guide line recommended classifications.1
  • Resolving HER2 IHC2+ equivocal results with FISH is challenging.1-4
  • Technical and observer variability can lead to approximately 20% inaccurate ER and PGR results.5
  • Ki-67 IHC scores deviate due to a lack of standardization.6

(1) Wolff AC et al. Recommendations for Human Epidermal Growth Factor Receptor
(2) Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol. 2013 Nov 1;31(31):3997-4013.
(3) Starczynski J et al. HER2 Gene Amplification in Breast Cancer. A Rogues’ Gallery of Challenging Diagnostic Cases: UKNEQAS Interpretation Guidelines and Research Recommendations. AM J Clin Pathol. 2012 Apr;137(4):595-605.
(4) Rakha A et al. Updated UK Recommendations for HER2 assessment in breast cancer. Clin Pathol. 2015 Feb;68(2):93-99. 
(5) Hammond MEH et al.  American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. J Clin Onc. 2010 Feb 23; 28(16): 2784-2795. 
(6) Polley MYC et a.l An International Ki67 Reproducibility Study. J Natl Cancer Ins. 2013 Dec 18;105(24):1897-906.

The Solution


Xpert® Breast Cancer STRAT4 paves the way for a standardized, precise and reliable ER/PGR/HER2/Ki-67 mRNA assessment in less than 2 hours

  • Xpert Breast Cancer STRAT4 delivers semi-quantitative determination of ER/PGR/HER2/Ki-67 mRNA levels in FFPE invasive breast cancer sections
    • CYFIP1* reference gene is used for sample normalization
    • Three controls included in each test
    • Software report allows for objective and easy result interpretation
    • External FFPE controls# available for identifying errors, shifts, trends and operator variabilities

CYFIP1: Cytoplasmic FMR1 interacting protein 1 

# For Research Use Only. Not for use in diagnostic procedure. Not reviewed by any regulatory body.

The Impact


Xpert Breast Cancer STRAT4 standardizes reproducible ER/PGR/HER2/Ki-67 assessment

  • Clear and accurate results empower oncologists.
  • Enables flexibility, simplicity and random access for a streamlined workflow 24/7.
  • Easy and fast test implementation.
  • Internal controls meet quality management requirements.
  • Robust test and workflow that doesn’t require a PCR laboratory.

Performance

Xpert Breast Cancer STRAT4 results are highly concordant with ER/PGR/Ki-67 IHC and IHC/FISH (HER2)7

Xpert Breast Cancer STRAT4 vs. IHC biomarker assessment PPA NPA OPA
ESR1/ER 97.2% 95.0% 97.5%
PR/PGR 89% 92.9% 89.8%
ERBB2/HER2 (Xpert vs IHC) 100% 92.4% 93.3%
ERBB2/HER2 (Xpert vs FISH) 100% 92.0% 93.3%
ERBB2/HER2 (Xpert vs. IHC+FISH) 100% 91.2% 92.4%
MKi-67/Ki-67 88.7% 100% 90.5%

Positivity detection cut-offs of Xpert Breast Cancer STRAT4 for ER/PGR/HER2 correlate with those in ASCO-CAP, St. Gallen Consensus and ESMO Guidelines.1,5,8,9

(7) Xpert® Breast Cancer STRAT4 Package Insert. Sunnyvale. USA. 2017
(8) Gnant M et al. St. Gallen/Vienna 2015: A Brief Summary of the Consensus Discussion. Breast Care. 2015 Apr;10(2):124-130.
(9) Senkus et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26 Suppl 5:v8-30.

Ordering Info


Xpert® Breast Cancer STRAT4

Number of Tests: 10

Catalog #: GXBSTRAT4-CE-10

Xpert® Breast Cancer STRAT4

Xpert® FFPE Lysis Kit Number of Tests: 10

Catalog #: GXFFPE-LYSIS-CE-10

Xpert® Breast Cancer STRAT4

Xpert Breast Cancer STRAT4 StartPAK containing  Xpert FFPE Lysis Kit and Xpert Breast Cancer STRAT4 Number of Tests: 20

Catalog #: GXBCSTRAT4-SPAK1*

Xpert® Breast Cancer STRAT4

Xpert Breast Cancer STRAT4 FFPE Controls# Number of Tests: 1 set for 3 tests

Catalog #: BCSTRAT4-BU1

Xpert® Breast Cancer STRAT4

Xpert Breast Cancer STRAT4 FFPE Controls# Number of Tests: 5 sets for 15 tests

Catalog #: BCSTRAT4-BU2

# For Research Use Only. Not for use in diagnostic procedures.

* CE-IVD. In Vitro Medical Device. Not available in the U.S. Not available in all countries.

^ Limited to one per customer.

Back to Top